Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

CEO Michael Mahoney highlighted the company’s exceptional performance in 2024, with operational sales growth of 23% in Q4 and 18.5% for the full year. Organic sales grew 20% in Q4, exceeding guidance.

Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth ...

Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the irregular heartbeat known as atrial fibrillation—and the sum more than ...

Boston Scientific said its fourth-quarter net income rose 12% amid robust demand for its stents, catheters and other cardiology devices. The Marlborough, Mass., medical-device maker posted ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

Medical device maker Boston Scientific forecast annual profit above Wall Street estimates on Wednesday, banking on steady demand for its heart devices.